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grelor, standard & high dose Clopidogrel in patients undergoing PCI.
PubMed, EMBASE, CENTRAL and clinicaltrials.gov were searched for
studies comparing Prasugrel, Ticagrelor, standard dose (SD) & high
dose (HD) Clopidogrel in patients undergoing PCI. Frequentist and
Bayesian random effect network meta-analyses were performed be-
sides random effect direct pairwise comparisons. Statistical analysis
was conducted using WinBugs and Stata software. Ranking of treat-
ments are based on surface under cumulative ranking curves (SUCRA)
derived from Bayesian analysis. SUCRA values provide chances of
being best drug in form of percentage (%).
RESULTS Thirty trials, with 34, 563 person years of follow up data
after PCI, were included in the analysis. Prasugrel (86%) emerged
as best drug to prevent deﬁnite or probable stent thrombosis,
followed by Clopidogrel HD (66%) and Ticagrelor (44%), with Clo-
pidogrel SD being the worst. Myocardial infarction was least likely
to be prevented by Clopidogrel SD (0%) after PCI, and rest three
were superior to it (Prasugrel 74%; Clopidogrel 70%; Ticagrelor
56%). Clopidogrel SD (18%) was least effective in preventing car-
diovascular deaths after PCI. Prasugrel (73%) was likely most
effective in preventing cardiovascular deaths followed by Ticagrelor
(62%) and Clopidogrel HD (47%). Ticagrelor (68%) reduced all-cause
mortality by a small margin compared to rest of treatments (Pra-
sugrel 50%; Clopidogrel 48%; Clopidogrel 34%). Clopidogrel SD
(79%), followed by Clopidogrel HD (53%) and Ticagrelor (48%),
resulted in signiﬁcantly lower TIMI major bleeding complications
compared to Prasugrel. Analysis of any bleeding revealed similar
trend. Clopidogrel HD performed better than Prasugrel in terms of
bleeding complications. Results of direct pairwise comparison and
network meta-analysis were consistent in the direct of overall ef-
fect (Figure).
CONCLUSIONS Prasugrel is most effective drug to prevent post PCI
ischemic events but at the expense of higher bleeding. Ticagrelor
followed by Clopidogrel HD appears to strike the right balance be-
tween efﬁcacy & safety.
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BACKGROUND Primary angioplasty is the best reperfusion treatment
in ST elevated myocardial infarction. The number of elderly patients
(> 75 years) undergoing primary angioplasty is progressively
increasing as population is ageing. The optimal antithrombotic ther-
apy during the procedure (bivalirudin vs. unfractioned heparin with
or without abciximab) is not deﬁned for this important subgroup of
patients.
METHODS Retrospective consecutive registry conducted in 31 centers
of patients > 75 years with ST elevation myocardial infarction un-
dergoing primary angioplasty.
RESULTS A total of 3,126 pts have been included, 2,029 (64.9%)
treated only with UFH, 750 (24%) with UFH+abciximab, 319 (10.2%)
with bivalirudin only and 28 (0.9%) with bivalirudin+abciximab.
Three groups were deﬁned: BIV (319), UFH (2.029) and UFH-A (750)
with mean ages 81.25, 81.6 4.7 and 79.6 4.3 years respectively
(p<0.001).. Outcomes at 12 months were the following: survival free of
cardiac death and MI was 85.6%, 80% and 83.4% (p¼0.01) in BIV, UFH
and UFH-A groups and TLR was 2.7%, 3% and 1.4% (p¼0.1) respec-
tively. Incidences of deﬁnite or probable stent thrombosis were 2.8%,
2.5% and 2.3% (p¼0.2) and incidences of bleeding BARC > 2 were
0.8%, 1.3% and 1.5% (p¼0.1) respectively.
CONCLUSIONS The most common antithrombotic treatment in pri-
mary angioplasty of the very elderly is based on UFH (89%) with the
use of abciximab in a 24% of cases. The use of bivalirudin was asso-
ciated with the lowest incidence of cardiac death and MI with no in-
crease in stent thrombosis. The rate of severe bleeding (BARC >2) was
comparable.
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Safety and efﬁcacy of policosanol in patients with high on-treatment
platelet reactivity after drug-eluting stent implantation
Kai Xu,1 Yi Li,1 Yaling Han1
1General Hospital of Shenyang Military Region, Shenyang, China
BACKGROUND Some patients have high residual platelet reactivity
on clopidogrel after coronary intervention and risk of thbombotic
events is high. The aim of the study was to investigate safety and
efﬁcacy of policosanol in patients with high on-treatment platelet
reactivity after drug-eluting stent implantation.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B81METHODS A total of 350 patients with acute coronary syndrome who
underwent drug-eluting stent implantation from 4 hospitals in China
were enrolled. All of them were with high on-treatment platelet
reactivity (HPR), which was deﬁned as adenosine diphosphate
induced platelet aggregation (by light transmission aggregometry)
>65%. All of them were treated with aspirin. Patients were random-
ized by the ratio of 1:3:3 to: Group A, clopidogrel 75 mg/d for one year
(n¼50) ; Group B, clopidogrel 150mg/d for 30 days followed by 75mg/
d until one year (n¼150); or Group C, policosanol 40mg/d for 6 month
and clopidgrel 75mg/d for one year (n¼150). The primary endpoints
was the reversion rate of HPR at one-month (reversion was deﬁned as
platelet aggregation <65%). The secondary endpoints were 12-month
major adverse cardiac events (MACE), which included cardiac death,
non-fatal myocardial infarction or ischemic symptoms driven target
vessel revascularization.
RESULTS At 30 days, the reversion rate of HPR were 34.0%, 55.2% and
48.7% in Group A, group B and group C, respectively (P¼0.029). MACE
occurred in 4 (8.0%), 6(4.0%) and 5(3.3%) patients (P¼0.342). There
was 1 (0.7%) major bleeding and 1 (0.7%) minor bleeding event in high
maintenance dose clopidogrel group, no major or moderate bleeding
in the other two groups. The minimal bleeding in Group B was
signiﬁcantly higher than Group C (10.7% vs 2.7%, P¼0.022).
CONCLUSIONS Policosanol reduced platelet reactivity to a similar
extent as high maintenance dose of clopidogrel without increasing
bleeding rate.
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BACKGROUND Female patients are at higher risk of contrast-induced
acute kidney injury (CIAKI) compared to males. In the multicenter,
prospective, TRACK-D study, short-term rosuvastatin has proven
effectively reduce CIAKI in patients with type 2 diabetes mellitus and
stage 2-3 chronic kidney disease (CKD). This study aimed to explore
the efﬁcacy of rosuvastatin in the female TRACK-D population.
METHODS This study was a gender-based analysis of 2998 patients
(1044 females) enrolled in the TRACK-D study and were randomized
to short-term (2 days before and 3 days after procedure) rosuvastatin
therapy or standard of care. The primary outcome was the incidence
of CIAKI and the secondary outcome was a composite of death, dial-
ysis/hemoﬁltration or worsening heart failure at 30 days.
RESULTS CIAKI incidence was comparable between male and female
patients in the overall study population (2.5% vs. 3.4%, p¼0.165) and
in the rosuvastatin group (2.4% vs. 2.1%, P¼0.72), while it was higher
for females in the control group (3.1% vs. 5.3%, P¼0.04). Female was
an independent risk factor of CIAKI (Odds ratio: 1.65, 95% conﬁdence
interval: 1.03-2.63, p¼0.036). Rosuvastatin treatment vs. control
lowered CIAKI rate in females (2.1% vs. 5.3%, relative risk ¼0.39, 95%
conﬁdence interval: 0.19-0.77, number needed to treat [NNT]¼31),
particularly among those with CKD stage 2 (1.2% vs. 4.1%, p¼0.011).
Secondary outcome incidence was similar for females in the rosu-
vastatin and control groups (3.7% vs. 4.9%, p¼0.37).
CONCLUSIONS Compared to males, untreated females with diabetes
mellitus and CKD had a higher risk of CIAKI, which can be reduced by
short-term rosuvastatin treatment.
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BACKGROUND Emerging evidence suggested a superiority of biva-
lirudin compared with heparin or heparin plus GPI, however,primarily restricted in patients undergoing transfemoral primary
percutaneous coronary intervention (PCI) and suffering relative
higher access site bleeding. This trial aimed to explore the safety and
efﬁcacay of bivairudin in patients underwent primary PCI via radial
access.
METHODS In the BRIGHT trial, a total of 2194 AMI patients
with planned emergency PCI were enrolled and randomized to
receive bivalirudin, heparin or heparin plus tiroﬁban. The present
study was a prespeciﬁed subgroup analysis of the BRIGHT trial that
compared 30-day outcomes in patients with radial access (n¼1723)
among bivalirudin (n¼576), heparin alone (n¼576) and heparin plus
tiroﬁban (n¼571) arms. The primary outcome was 30-day net
adverse clinical event (NACE), deﬁned as a composite of major
cardiac and cerebral events (MACCE, including all-cause death, re-
infarction, ischemia-driven target vessel revascularization or stroke)
or any bleeding.
RESULTS Among patients of radial access, the primary outcome of 30-
day NACE occurred in 5.7% with bivalirudin, 7.8% with heparin alone
(vs bivalirudin, P¼0.159), and 10.3% with heparin plus tifoﬁban (vs
bivalirudin, P¼0.004). The 30-day bleeding rate was 0.9% for biva-
lirudin, 2.3% for heparin, and 5.8% for heparin plus tiroﬁban
(P<0.001). The rates of MACCE (4.9% vs 5.7% vs 4.6%, P¼0.899), stent
thrombosis (0.5% vs 0.5% vs 0.7%, P¼0.899) and acquired thrombo-
cytopenia (0.2% vs 0.5% vs 0.9%, P¼0.257) at 30 days were similar
among three arms.
CONCLUSIONS In patients with radial access, bivalirudin kept supe-
rior over heparin plus tiroﬁban on reducing 30-day NACE, primarily
due to the decrease in bleeding events. Although with no statistical
signiﬁcance, bivalirudin brought improvement on the primary
outcome compared with heparin monotherapy.
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BACKGROUND Female patients are at higher risk of both bleeding
and ischemic events during percutaneous coronary interventions
(PCI). The aim of the present study was to evaluated the safety and
efﬁcacy of bivalirudin during emergency PCI in female patient with
acute myocardial infarction (AMI).
METHODS Study population was derived from the BRIGHT trial, a
multi-center, randomized, active drug-controlled clinical trial. A
total of 392 female patients were enrolled in the BRIGHT trial,
including 127 patients randomized to the bivalirudin group and 265
patients randomized to the control group (heparin with or without
tiroﬁban). The primary efﬁciency endpoint was 30-day net adverse
clinical event (NACE), deﬁned as all-cause death, re-infarction,
ischemia-driven target vessel revascularization, stroke or any
bleeding. The second efﬁciency endpoints was 30-day major cardiac
and cerebral events (MACCE), deﬁned as all-cause death, re-
infarction, ischemia-driven target vessel revascularization and
stroke.
RESULTS The incidence of 30-day NACE (6.3% vs. 21.5%, p＜
0.001), any bleeding (2.4% vs. 12.8%, p¼0.001) and BARC 2-5 type
bleeding (1.6% vs. 7.2%, p¼0.021) in the bivalirudin group were lower
than that in the control-group. The incidence of MACCE （3.4% vs.
9.4%, p¼0.55) and stent thrombosis（0% vs. 1.1%, p¼0.229） were
comparable between the two groups. Multivariate COX analysis
showed that, bivalirudin (odds ratio [OR]:0.245, 95% conﬁdence in-
terval [CI]: 0.113-0.532, p< 0.001), transradial access (OR: 0.119, 95%
CI: 0.067-0.211, p＜0.001), and statin (OR: 0.254 , 95%CI: 0.08-0.807,
p¼0.02) were independent protective factors for 30-day NACE in fe-
male patients.
CONCLUSIONS The risk of bleeding and the incidence of 30-day
adverse events were higher in female patients compared to male
patients. In this high risk patient cohort, compared to heparin with
or without tiroﬁban, use of bivalirudin during the perioperative
period of emergency PCI signiﬁcantly reduces the incidence of
bleeding with similar anticoagulation effects.
